| abstract |
The invention relates to the new phosphoinositide 3-kinase (PI3K) and rapamycin blank inhibitor compounds in mammals (mTOR), which have the formulas (I) and (II), which are conformationally restricted and for, which, the meaning of the substituents is listed in the description. Preferred compounds are those wherein X is oxygen, R1 is a morpholino and R2 is a substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with other therapeutic agents, for the treatment of lipid kinase mediated disorders. (See Formula). |